The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

Part of you is concerned — after all, you know depression can be serious — but on the other hand, can’t weight loss be a good ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

It's become increasingly clear that the gut microbiome can affect human health, including mental health. Which bacterial ...

A new report studied depression levels across Europe and in older and younger individuals, with the outlook for France ...

The U.S. Food and Drug Administration on Tuesday approved the first nasal spray that will help with treating major depressive ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...

When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young ...

The selective serotonin reuptake inhibitor sertraline is often among the preferred antidepressants to take when breastfeeding ...

Presence of a protein-binding biomarker in a small cohort of adults with depression may be an indicator that suicidal ...